Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-03-07 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-03-07 English
Appendix 3Y for Eric Rose 3 pages 300.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including shares acquired and disposed, dates of changes, and consideration amounts. The content is focused on reporting personal share transactions by a company director. There is no financial performance data, earnings information, or report publication announcement. The document fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is 4143 characters, consistent with a detailed insider trading notice rather than a full financial report or announcement.
2025-03-06 English
Notification regarding unquoted securities - MSB 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance and conversion of unquoted securities into quoted ordinary shares. It includes specifics such as the number of securities issued, dates, and mentions key management personnel involved in the transactions. The document is a formal notification to the ASX regarding changes in the company's capital structure through the issuance and conversion of securities. This matches the definition of a 'Share Issue/Capital Change' filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement about securities issuance. Therefore, the correct classification is SHA (Share Issue/Capital Change). The document length and detail support a high confidence level.
2025-03-06 English
Appendix 3Y for Jane Bell 2 pages 256.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market share purchase), and other related information. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The document length is 3633 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2025-03-06 English
Appendix 3Y and replacement Appendix 3X for Gregory George 7 pages 436.5KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y and replacement Appendix 3X filing related to changes in a director's shareholdings and interests. These forms are regulatory filings required by the Australian Securities Exchange (ASX) to disclose directors' interests in securities. The content details share purchases by a recently appointed director, Dr. Gregory George, including the number of shares held before and after the transaction, dates of changes, and nature of the transactions. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of director's dealings in shares, which fits the definition of Director's Dealing (DIRS). The document length (8137 characters) and detailed disclosure confirm it is not a brief announcement or a report publication announcement. Therefore, the correct classification is DIRS with high confidence.
2025-03-06 English
Mesoblast Added to S&P ASX200 Index 2 pages 202.2KB
Investor Presentation Classification · 85% confidence The document is a press release announcing Mesoblast Limited's addition to the S&P/ASX 200 Index. It provides company background, product information, intellectual property details, manufacturing capabilities, and forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is informational and promotional in nature, typical of a corporate announcement or investor relations update. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being published or attached. The content aligns best with an Investor Presentation (IP) or a general corporate announcement. Given the detailed company and product information aimed at investors and the market, the most appropriate classification is Investor Presentation (IP).
2025-03-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.